We take risks and challenge the status quo because disease must be fought with unexpected practice.
Unlike traditional therapeutic approaches that target growth factors in their active states, Scholar Rock uses its technology platform and structural insights to discover new medicines designed to selectively target the precursor, or inactive, forms of growth factors with the aim of avoiding toxicity and improving efficacy.Learn About Our Science
Scholar Rock works across therapeutic areas and shines new light on the overlooked to better target disease.
Our growing team is replete with good people who eat, sleep, and breathe good science. We promote a spirit of inquiry outside one’s traditional expertise to uncover enlightened solutions for patients.
Spinal Muscular Atrophy
In partnership with Gilead Sciences
April 10, 2021
Scholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Association for Cancer Research Annual Meeting
April 6, 2021
Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
March 22, 2021
Scholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of Toxicology